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Abstract
Rationale: Bedaquiline and delamanid offer the possibility of more
effective and less toxic treatment for multidrug-resistant (MDR)
tuberculosis (TB). With this treatment, however, some patients remain at
high risk for an unfavorable treatment outcome. The endTBObservational
Study is the largest multicountry cohort of patients with rifampin-resistant
TBorMDR-TBtreatedinroutinecarewithdelamanid-and/orbedaquiline-
containing regimens according toWorld Health Organization guidance.
Objectives:We report the frequency of sputum culture conversion
within 6 months of treatment initiation and the risk factors for
nonconversion.
Methods:We included patients with a positive baseline culture who
initiated a first endTB regimen before April 2018. Two consecutive
negative cultures collected 15 days or more apart constituted culture
conversion. We used generalized mixed models to derive marginal
predictions for the probability of culture conversion in key
subgroups.
MeasurementsandMainResults:Atotalof1,109patients initiateda
multidrug treatment containing bedaquiline (63%), delamanid (27%), or
both (10%). Of these, 939 (85%) experienced culture conversion within 6
months. In adjusted analyses, patientswithHIVhad a lower probability of
conversion (0.73; 95% confidence interval [CI], 0.62–0.84) than patients
withoutHIV(0.84;95%CI,0.79–0.90;P=0.03).Patientswithbothcavitary
disease and highly positive sputum smear had a lower probability of
conversion (0.68; 95% CI, 0.57–0.79) relative to patients without either
(0.89; 95% CI, 0.84–0.95; P=0.0004). Hepatitis C infection, diabetes
mellitus or glucose intolerance, and baseline resistancewere not associated
with conversion.
Conclusions: Frequent sputum conversion in patients with rifampin-
resistantTBorMDR-TBwhowere treatedwithbedaquiline and/ordelamanid
underscores theneed forurgentexpandedaccess to thesedrugs.There is aneed
to optimize treatment for patients withHIV and extensive disease.
Keywords: multidrug-resistant tuberculosis; rifampicin-resistant
tuberculosis; sputum conversion; interim outcome; extensively
drug-resistant tuberculosis
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Multidrug-resistant (MDR) tuberculosis
(TB) is catastrophic to patients, communities,
and health systems. Defined as disease
caused by Mycobacterium tuberculosis that
is resistant to rifampin and isoniazid,
the two most potent drugs used in
standard first-line therapy, MDR-TB,
together with rifampin-resistant (RR)
TB, sickens more than 500,000 people
annually (1). Historically, patients
endured a grueling 18- to 24-month
MDR-TB treatment regimen that cured
only 55%. Among patients whose TB
was caused by M. tuberculosis also
resistant to a fluoroquinolone and a
second-line aminoglycoside or polypeptide
(i.e., extensively drug-resistant [XDR] TB),
only 34% were cured (2). Debilitating side
effects limited patients’ ability to complete
treatment and had lasting social and
economic consequences (3–7).
In 2012 and 2013, on the basis of
promising phase II trial data (8–10),
stringent regulatory authorities approved
the first new TB drugs in 50 years,
bedaquiline (BDQ) and delamanid (DLM),
offering hope for more effective and less
toxic MDR-TB treatment. Since then,
evidence generated from both randomized
trials and observational studies has
continued to support a role for these two
drugs in MDR-TB treatment (11–20); the
World Health Organization (WHO) has
endorsed their use, gradually broadening
the populations in which they might be
used (21–23). Patients with MDR-TB often
experience conditions that increase the risk
of unfavorable treatment outcomes
(e.g., HIV and/or hepatitis C virus [HCV]
coinfection, diabetes mellitus [DM], and/or
XDR-TB) (24–30). It is critical to
understand whether WHO-conforming
regimens containing BDQ and/or DLM can
produce successful outcomes in these
vulnerable subgroups in routine care.
Because such patients are often excluded
from trials, we undertook the endTB
Observational Study in a diverse
prospective cohort of patients treated for
MDR-TB with BDQ- or DLM-containing
regimens in 17 countries (Armenia,
Bangladesh, Belarus, Democratic People’s
Republic of Korea, Ethiopia, Kenya,
Georgia, Haiti, Indonesia, Kazakhstan,
Kyrgyzstan, Lesotho, Myanmar, Pakistan,
Peru, South Africa, and Vietnam) (31).
Here, we 1) report interim effectiveness
outcomes (i.e., sputum culture conversion
within 6 mo of treatment initiation)
overall and among high-risk patients
underrepresented in studies published to
date and 2) examine which subgroups
experienced a higher risk of an unfavorable
interim effectiveness outcome.
Methods
Study Design and Patient Population
The endTB Observational Study
(NCT02754765) comprises a prospective
cohort of patients with RR-TB or MDR-TB
who were treated with BDQ and/or
DLM (31) according to WHO indications
at the time (22, 23). A common study
protocol guided data collection across
participating sites (31). Treatment
comprised longer (18 mo or more)
individualized treatment regimens
composed according to national TB
program guidelines and informed by
the endTB clinical guide (32). Data
collection was standardized across sites
and organized by the endTB consortium
partners. For this analysis, we included
patients who received a first endTB
treatment regimen for RR-TB or MDR-TB
between April 1, 2015, and March 31,
2018, and had a positive baseline sputum
culture. Patients living with HIV and HCV
comprised key subgroups; therefore, we
excluded all 16 patients in the Democratic
People’s Republic of Korea, where HIV
testing was not conducted and quality
control assessments suggested that early
HCV test results were invalid.
Outcome
The outcome of interest was sputum culture
conversion within the first 6 months of
treatment, which correlates with end of
treatment outcomes (33, 34) and is used as
a standard interim endpoint in studies of
MDR-TB treatment (8, 10, 13).
The endTB Observational Study was funded by Unitaid.
Author Contributions: Conceived of the study: M.F.F., P.K., C.H., U.K., H.H., K.J.S., M.L.R., M.B., and C.D.M. Led data analyses: M.F.F. Contributed to data
analysis plan: P.K., S. Atwood, M.B., and C.D.M. Designed the study: all authors. Oversaw study implementation and data acquisition: all authors. Wrote first
draft of manuscript: M.F.F. Approved final version: all authors.
Data sharing statement: Upon publication, we will make available deidentified data and a corresponding data dictionary in addition to the study protocol and
informed consent form. Requests can be submitted by e-mail to the corresponding author. Data will be shared after endTB Consortium approval of a proposal
and execution of a data-access agreement.
At a Glance Commentary
Scientific Knowledge on the
Subject: Few large studies have
reported the frequency of unfavorable
treatment outcomes and associated
factors from patients receiving
bedaquiline and/or delamanid for
rifampin-resistant (RR) or multidrug-
resistant (MDR) tuberculosis (TB)
treatment.
What This Study Adds to the Field:
The endTB Observational Study
comprises the largest multicountry
cohort of patients receiving
bedaquiline or delamanid as part of a
regimen for RR-TB or MDR-TB and
includes broad representation from
patients known to be at high risk for
unfavorable treatment outcomes.
Among 1,106 patients treated
programmatically in one of 16
countries on five continents, we found
that 85% of patients experienced a
favorable interim outcome
(i.e., conversion of sputum from
positive to negative) within 6 months.
Patients living with HIV and those who
presented with both a high smear grade
and cavitary disease were at higher risk
of no sputum culture conversion
within 6 months. Patients with
extensively drug-resistant TB, hepatitis
C virus infection, and/or diabetes
mellitus or glucose intolerance
experienced a similar frequency of
sputum conversion relative to patients
without these conditions. Continued
work is needed to optimize RR-TB or
MDR-TB treatment for patients with
TB characterized by high smear grade
and cavitary disease and for patients
living with HIV infection.
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Definitions
Culture conversion within 6 months was
defined as two consecutive negative cultures
collected at least 15 days apart, the first
occurring before 180 days of treatment and
the second occurring before 210 days of
treatment. We classified patients into
subgroups based on HIV infection, HCV
infection, DM or glucose intolerance (GI),
TB drug resistance category, and a
composite variable considering sputum
smear grade (31 vs. ,31) and the
presence of cavitation on chest radiograph
(yes or no). Baseline HIV and HCV
infection as well as DM or GI were
determined foremost by laboratory testing.
We also considered information in the
clinical chart regarding the presence or
explicit absence of these conditions.
Baseline drug resistance category (i.e., RR-
TB or MDR-TB, pre–XDR-TB with
fluoroquinolone resistance, pre–XDR-TB
with injectable resistance, and XDR-TB)
was determined based on all prior available
drug susceptibility test results. Extensive
disease was established by the presence of
both a 31 positive baseline sputum smear
and cavitary disease. This definition was
derived from a recent study that found that
patients with these characteristics may
require longer or more intensive treatment
(35).
Statistical Analyses
We estimated the proportion of patients
who experienced the outcome of interest.
We also calculated the frequency of
conversion in the subgroups described
above and examined whether these
characteristics were associated with
conversion. To do this, we conducted
multivariable regression analyses using
generalized mixed models with a log link (or
logit link if the model did not converge) and
a random intercept for country. We derived
the marginal predictions of the probability
of conversion for each subgroup (36) and
compared them using x2 tests.
Secondary analyses examined effect
modification of HIV by CD4 (cluster of
differentiation 4) cell count and the effect
modification of DM by glycemic control. To
examine whether any increased risk of
nonconversion among patients with HIV
was due to death or loss, we reran analyses
excluding deaths and losses occurring in the
first 6 months and before conversion. The
online supplement includes information on
sensitivity analyses, including another
multivariable analysis in which we adjusted
for additional covariates.
Research Ethics
The endTB Observational Study protocol
was approved by central ethics review
committees for each consortium partner,
and local ethical approval was obtained in all
endTB countries. Participants provided
written informed consent for inclusion in
the observational cohort.
Additional information regarding
study methods, including eligibility criteria,
definitions, and statistical analyses, can be
found in the online supplement.
Results
Overview
Of 2,195 patients initiating a first regimen
for RR-TB or MDR-TB with endTB during
the study period, 2,071 (94%) consented to
participate in the observational study. This
analysis included the 1,109 patients with a
positive sputum culture within the 90 days
before the earliest initiation of BDQ or DLM
(Figure 1). Patients living with HIV
commonly had no positive culture and
were, therefore, included less often in
conversion analyses than patients without
HIV (43% vs. 56%, respectively). In
contrast, patients with HCV, DM or GI,
and XDR-TB were more often included
than patients without these conditions
(62% vs. 54%, 62% vs. 53%, and 64% vs.
54%, respectively).
The 1,109 included patients were
treated in 16 endTB countries (Table E1 in
the online supplement) and initiated a
multidrug regimen containing BDQ (63%),
DLM (27%), or both (10%) (Table 1).
Linezolid and clofazamine were commonly
used, with 82% and 73% of patients
receiving these repurposed drugs in their
baseline regimen. One-third of the cohort
were female, and the median age was 36
years (interquartile range, 27–46) (Table 1).
Comorbidities were common; 119 patients
(11%) were living with HIV, 144 (13%)
were living with HCV, and 181 (17%) met
the definition of DM or GI. XDR-TB was
found in 389 (36%) patients. Thirteen
percent of patients had extensive disease,
and 75% had received prior treatment with
second-line TB drugs. Among patients
living with HIV, 72% (86/119) were known
to be on antiretroviral treatment (ART) at
the time of BDQ or DLM initiation, and of
those with a baseline CD4 cell count, 52%
had a value ,200 cells/ml. Relative to
patients without HIV, patients living with
HIV were more likely to be smear negative
(44% vs. 26%, respectively). Eighty percent
of patients with DM or GI (n= 145) had a
baseline HbA1c result; DM was poorly
controlled in 57%.
Sputum Culture Conversion
Overall, 939 (85%) patients experienced
sputum culture conversion within 6 months.
Excluding contaminated cultures, the
median number of cultures per person was 5
(interquartile range, 4–6). Fifty-four
patients (5%) had no follow-up cultures
and were considered not to have
experienced culture conversion. Of these,
the majority (64%, n= 34) died or were lost
to follow-up, and 90% of these outcomes
occurred during the first 3 months of
treatment. In univariable analyses, living
with HIV or HCV or having extensive
disease were risk factors for not
experiencing culture conversion within
6 months (Table 2). In contrast, the
proportion of patients who experienced
sputum culture conversion within 6 months
did not differ according to baseline
resistance category or whether the patient
had DM or GI. In the multivariable
analyses, only HIV infection and extensive
disease were independent risk factors for
not experiencing culture conversion within
6 months (Figure 2 and Table E2).
Adjusting for resistance category, HCV
infection, DM or GI, extensive disease, and
year of enrollment, patients living with HIV
had a marginal predicted probability of
conversion of 0.73 (95% confidence
interval [CI], 0.62–0.84) compared with a
probability of 0.84 (95% CI, 0.79–0.90)
among patients without HIV infection
(P= 0.03). Extensive disease was associated
with a lower probability of conversion
(0.68; 95% CI, 0.57–0.79) relative to
patients who had neither cavitary disease
nor a sputum smear result of 31 (0.89; 95%
CI, 0.84–0.95; P= 0.0004).
Secondary analyses suggested that HIV
infection was a more important risk factor
for patients with a CD4 cell count of 200
cells/ml or more relative to those with a
CD4 cell count ,200 cells/ml (Table 3).
HIV remained similarly associated with
nonconversion after excluding 71 patients
who died or were lost to follow-up before
conversion (adjusted odds ratio for full
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cohort of 1,103, 2.12 [95% CI, 1.13–3.97]
vs. 2.09 [95% CI, 0.90–4.85] with 71
exclusions). The effect of DM or GI on
culture conversion was similar among
patients with and without glycemic control
at baseline (Table 3).
Results from a multivariable model
in which we adjusted for additional
covariates were qualitatively similar to
results from the primary model (Table E2).
Results of other sensitivity analyses did
not change the interpretation of findings
(Table E3).
Discussion
When national TB programs and partners
used BDQ and DLM alongside repurposed
drugs such as linezolid in RR-TB or MDR-
TB treatment regimens according to WHO
guidance, a high proportion of patients
experienced sputum culture conversion by 6
months. endTB Observational Study
findings are in line with trials and smaller
observational cohorts, which have generally
reported 6-month conversion outcomes
ranging from 70% to 90% (10, 11, 13, 19,
37). This is notable because the endTB
cohort included patient groups that are
often excluded from trials (i.e., those with
HIV and low CD4, XDR-TB, previous
treatment for MDR-TB, uncontrolled
DM, or coinfection with HIV and hepatitis
B or C) (10, 13). Importantly, relative to
culture conversion analyses that censor
patients who die, become lost to follow-up,
or lack follow-up cultures (e.g., Kaplan-
Meier estimates), our approach was
conservative in that we classified these
patients as having an unfavorable interim
outcome (i.e., no conversion) rather than
censoring them.
Historically, patients with XDR-TB
have experienced a higher risk of
unfavorable treatment outcomes than
patients with less resistant TB (2). This was
not the case in our study. This is likely
because the addition of BDQ and DLM as
well as repurposed drugs (i.e., linezolid and
clofazimine) allowed for the construction of
therapeutic TB regimens for these patients,
which had previously been impossible.
However, patients living with HIV and
those with extensive disease were less likely
to experience culture conversion within 6
months. Variable interim treatment success
across patient subgroups highlights the
importance of stratifying and standardizing
estimates when drawing comparisons
between cohorts.
The combination of a high smear grade
and cavitary disease (a phenotype that
predicted poor outcomes in a meta-analysis
of randomized clinical trials of shortened
rifamycin-containing regimens for drug-
susceptible TB) (35) was also associated
with poor interim outcomes among
patients with MDR-TB receiving longer
(18 mo or longer) regimens. Identifying
optimal treatment strategies for this
subgroup is an important research priority,
especially in light of movement toward all-
oral shortened regimens.
In secondary analyses, we found some
evidence that the lower frequency of culture
conversion experienced by patients living
with HIV was more pronounced among
those who had high CD4 cell counts. This
may be a chance finding and must be
interpreted with caution because of small
numbers and some missing data for baseline
CD4 cell count. On the other hand, among
patients living with HIV, TB may present
differently across the spectrum of CD4 cell
counts; patients with lower CD4 cell counts
are more likely to have paucibacillary
sputum and less parenchymal involvement,
and, therefore, their sputum may convert to
culture negative more quickly (38, 39).
Although TB in patients with HIV and
higher CD4 cell count may present more
like that observed in HIV-negative patients
(e.g., with higher smear grade and cavitary
disease), underlying HIV-related immune
deficits might still preclude a comparable
treatment response. Furthermore, the
development of TB disease in patients with
high CD4 cell counts may induce HIV
disease progression and death (40). Our
findings highlight an urgent need to
optimize MDR-TB treatment outcomes
among patients living with HIV. One recent
study raised the possibility that the ART
modifications required for patients
receiving BDQ might increase pill burden
and decrease adherence (41). New WHO
recommendations for once-daily
dolutegravir-containing ART (42) will ease
the difficulties of modifications previously
required for patients living with HIV who
are receiving BDQ.
Patients with HCV infection may be at
increased risk of unfavorable TB treatment
outcomes because of an increased risk of
anti-TB drug–induced liver injury (43),
limited treatment options resulting from
anti-TB drug–induced liver injury, or
shared risk factors for HCV and MDR-TB
that may also place them at higher risk
(i.e., substance abuse). In univariable
analyses, HCV was associated with a 45%
increase in the risk of nonconversion within
6 months (95% CI, 1–107%). After
adjustment for other comorbid conditions,
TB drug resistance category, and extensive
disease, this indicator of HCV infection
was associated with only a small to
moderate increase in the probability of
2,195 patients initiated a first regimen*
containing BDQ and/or DLM with endTB
between April 1, 2015, and March 31, 2018
2,071 (94%) provided informed consent
2,058 (99%) included in research cohort
1,109 (54%) included in this analysis
949 (46%) excluded
Negative baseline culture (n=687)
Missing baseline culture (n=246)
Patients from DPRK (n=16)
13 (<1%) excluded for rifampicin
sensitivity
Figure 1. Overview of the analysis cohort. *During the study period, 12 patients initiated a
second regimen with endTB containing bedaquiline and/or delamanid. These second regimens
were excluded from analyses. BDQ=bedaquiline; DLM=delamanid; DPRK=Democratic People’s
Republic of Korea; TB= tuberculosis.
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Age at treatment initiation, yr, median (interquartile range; range) 36 (27–46; 12–82)
Sex, F 365 (33)
Comorbidities
Diabetes mellitus or glucose intolerance (n=1,089) 181 (17)
Poorly controlled diabetes mellitus (HbA1c .8.0%) (n=145)* 83 (57)
HIV infection 119 (11)
CD4 cell count (n=93), median (interquartile range; range)† 194 (58–305; 4–722)
CD4 cell count ,200 cells/ml (n = 93)† 48 (52)
On antiretroviral treatment (n=114) 86 (75)
Months on antiretroviral treatment, median (interquartile range; range) (n=84) 25 (4–76; 0–188)
Hepatitis B virus infection (n=1,103)‡ 46 (4)
Hepatitis C virus infection (n=1,103)x 144 (13)
At least one comorbidity other than those above 115 (10)
TB-related characteristics
Prior TB treatment with second-line drugs 832 (75)
Bilateral disease (n=1,017)k 726 (71)
Cavitary disease (n=999)k 658 (66)





Cavitary disease and smear status (n=980)
No cavitary disease, smear ,31 292 (30)
Cavitary disease, smear ,31 520 (53)
No cavitary disease, smear 31 40 (4)
Cavitary disease, smear 31 (extensive disease) 128 (13)
Resistance profile (n=1,094)
RR-TB or MDR-TB without any injectable or fluoroquinolone resistance 223 (20)
RR-TB or MDR-TB without any injectable or fluoroquinolone testing 50 (5)
RR-TB or MDR-TB with any injectable resistance¶ 104 (10)
RR-TB or MDR-TB with any fluoroquinolone resistance** 328 (30)
XDR-TB 389 (36)
Body mass index, 18.5 (n=1,099) 483 (44)
Only WHO indication for BDQ or DLM was TB drug toxicity†† 149 (13)
Drugs comprising the baseline regimen
BDQ (without DLM) 696 (63)
DLM (without BDQ) 303 (27)
Both BDQ and DLM 110 (10)






Imipenem and cilastatin or meropenem and amoxicillin-clavulanate 240 (22)
Prothionamide or ethionamide 463 (42)
Cycloserine 735 (66)
P-aminosalicylic acid 313 (28)
Number of likely effective drugs included in baseline regimen, median (interquartile range; range)‡‡ 5 (4–5; 0–8)
Definition of abbreviations: BDQ=bedaquiline; CD4=cluster of differentiation 4; DLM=delamanid; MDR=multidrug resistant; RR= rifampin-resistant;
TB= tuberculosis; WHO=World Health Organization; XDR=extensively drug resistant.
Results are n (%) unless otherwise noted.
*For the purposes of assessing diabetes mellitus disease control, we considered HbA1c results taken up to 90 days before initiation of the BDQ- or
DLM-containing regimen or up to 15 days after, with preference given to before.
†Baseline CD4 cell count was determined based on the most recent laboratory value corresponding to the 180 days before initiation of a BDQ- or
DLM-containing regimen with endTB. In the absence of a laboratory result, the CD4 cell count recorded on the baseline clinical form was used.
‡Hepatitis B virus surface antigen positive.
xHepatitis C virus antibody positive.
kBaseline chest radiograph was taken before initiation of the BDQ- or DLM-containing regimen or up to 15 days after (with preference given to before).
¶Four people in this group lacked a fluoroquinolone susceptibility test result.
**One person in this group lacked an injectable susceptibility test result.
††A regimen of at least four likely effective drugs could not be constructed due to toxicity (vs. resistance).
‡‡A drug was considered likely effective if 1) all reported testing (phenotypic or genotypic) to that drug confirmed susceptibility or 2) no resistance to the
drug was reported and the patient had not previously received the drug for 1 month or more. Otherwise, the drug was not considered likely effective.
ORIGINAL ARTICLE
Franke, Khan, Hewison, et al.: Culture Conversion in Patients Treated with BDQ and/or DLM 115
 
nonconversion, and the CIs around this
estimate were wide, falling below 1. Many
endTB country sites tested for antibodies to
HCV rather than antigen or viral load and
therefore could not distinguish between
chronic and cleared infections. Because
infection is spontaneously cleared in
approximately 30% of individuals infected
with HCV, it is likely that some participants
who were HCV antibody positive did not
have chronic infection (44). If chronic, but
not past, transient HCV infection decreases
the probability of conversion within 6
months, this misclassification could have
attenuated our effect estimates for HCV
(i.e., a true positive association between
active HCV infection and absence of
conversion would be underestimated or
null). Future research should examine
whether patients with HCV viremia are at a
higher risk for unfavorable outcomes and
how treatment with direct-acting antivirals
may mitigate any increased risk.
Although patients with TB and DM are
more likely to experience adverse treatment
outcomes, including death, relapse, and
absence of early sputum culture conversion,
relative to patients with TB but no DM (25),
we did not observe an association between
DM or GI and culture conversion within 6
months. Recent evidence suggests that
glycemic control may reduce the risk of
adverse outcomes among patients with
TB and DM (25). If patients in our study
went on to experience glycemic control,
this could explain the absence of an
association between baseline DM or GI
and culture conversion. A limitation to our
classification of DM or GI was that because
DM testing occurred programmatically,
patients may have been referred for
confirmatory testing, and these results were
not always available for research purposes.
Therefore, in some instances we were
unable to distinguish between a diagnosis of
DM and an episode of GI.
In addition to illustrating that overall
good interim outcomes were sustained in
several high-risk subgroups, these analyses
highlight another unique feature of this
study, as follows: TB programs had the
option of using BDQ or DLM in patients
included in this observational cohort. The
choice was made according to local policy
andWHO indications in effect at the time of
the study, which were different for the two
drugs (only BDQ was recommended for
patients in whom a regimen of at least
four likely effective drugs could not be
constructed because of toxicity or resistance
generally; DLM use was suggested for
patients with high risk for an unfavorable
treatment outcome; and either [or both]
could be used for patients with resistance to
fluoroquinolones and/or injectable agents)
(22, 23). Consequently, the results presented
herein are the comprehensive, programmatic
result achieved through the sum of
clinicians’ interpretations of this guidance
across 16 countries; the comparison of
results of regimens containing one or the
other of these drugs is not, therefore,
appropriate. Instead, we aim to inform
programs about the range of results that
could be expected if both drugs were used
according to the WHO guidance in place
between 2015 and 2017, when the endTB
Observational Study cohort was enrolled.
Table 2. Frequency of Sputum Culture Conversion among High-Risk Subpopulations Receiving an MDR-TB Regimen Containing




Univariable Risk Ratio for
Nonconversion [Ratio (95%
Confidence Interval)] P Value
All patients 939/1,109 0.85 — —
HIV infection
Negative 857/990 0.87 Reference
Positive 82/119 0.69 1.75 (1.16–2.65) 0.007
Hepatitis C infection
Negative 826/959 0.86 Reference
Positive 112/144 0.78 1.45 (1.01–2.07) 0.04
Diabetes mellitus or glucose intolerance*
No 764/908 0.84 Reference
Yes 161/181 0.89 0.80 (0.52–1.23) 0.31
Baseline resistance* 0.17†
MDR without additional resistance 185/223 0.83 Reference
MDR without injectable and
fluoroquinolone testing
42/50 0.84 0.90 (0.46–1.77) 0.76
Pre-XDR with injectable resistance 87/104 0.84 0.89 (0.53–1.51) 0.67
Pre-XDR with fluoroquinolone
resistance
291/328 0.89 0.67 (0.44–1.04) 0.07
XDR 324/389 0.83 1.14 (0.76–1.69) 0.53
Cavitary disease and smear status* ,0.0001†
No cavitary disease, smear ,31 265/292 0.91 Reference
Cavitary disease, smear ,31 456/520 0.88 1.23 (0.79–1.91) 0.35
No cavitary disease, smear 31 30/40 0.75 2.72 (1.49–4.95) 0.001
Cavitary disease, smear 31 (extensive
disease)
91/128 0.71 2.94 (1.84–4.68) ,0.0001
Definition of abbreviations: BDQ=bedaquiline; DLM=delamanid; MDR=multidrug resistant; TB= tuberculosis; XDR=extensively drug resistant.
*Univariable model included a missing indicator variable.
†Type III test.
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The following limitation of this study is
inherent in the use of sputum culture
conversion as the endpoint: analysis is
necessarily restricted to patients with a
positive baseline sputum culture.
A large proportion of patients in this
and other cohorts do not meet this
criterion and, therefore, are excluded
from interim analyses, potentially limiting
generalizability. There were several reasons
for initiating treatment without a positive
baseline culture. First, some patients were
diagnosed with TB on the basis of molecular
tests, such as GeneXpert, rather than
culture. Second, in some patients, BDQ or
DLM replaced a toxic drug in an ongoing
MDR-TB regimen (at least 13% of this
cohort). Third, we limited the period in
which cultures could be counted as
“baseline” to 90 days before the first
initiation of BDQ or DLM. Patients were
not included in this analytic cohort if their
most recent positive culture preceded this
window. Last, some patients, including
children, are unable to produce the sputum
sample needed for culture or simply have
culture-negative pulmonary TB disease. An
interim indicator of treatment success is
equally important for patients who initiate
treatment with a positive or negative
culture result. Validating an interim
outcome that can also be applied to patients
who do not initiate treatment with a
positive sputum culture is an important
area of future research.
A lack of informed consent precluded
the inclusion of a minority of eligible
patients in the observational study (6%).
These exclusions could introduce bias if
associated with a risk factor of interest
(e.g., HIV infection) and culture conversion.
Although we were not able to compare the
characteristics of patients who did and did
not provide consent, we expect that this
potential bias to be limited by the high
participation rate. A third limitation relates
to our use of the odds ratio as a measure of
association when the binomial model failed
to converge. The odds ratio will be farther
from the null value than the corresponding
risk ratio, with discrepancies between the
two measures increasing as the effect size
and risk of the outcome increase. In our
cohort, the outcome of nonconversion
occurred at a frequency of 15%; therefore,
the odds ratios may be most usefully
interpreted as relative risks for the purposes
of qualitative, rather than literal,
assessments of effects (45). To circumvent
this limitation of the odds ratio and to
facilitate the interpretation and assessment
of effect size, our primary analyses
report average marginal probabilities of
conversion. Fourth, local laboratory
capacity and norms determined whether
cultures were grown in liquid or solid
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Figure 2. Marginal predictions of the probability of culture conversion within 6 months, according
to baseline (A) extent of disease, (B) resistance pattern, and (C) presence of comorbidity (n=1,103).
Each probability is adjusted for the other covariates shown in this panel and year of enrollment.
CI =confidence interval; FQ=fluoroquinolone resistance; Hep C=hepatitis C; INJ= injectable
resistance; MDR=multidrug resistant; XDR=extensively drug resistant.
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medium, and we did not analyze whether
culture type impacted culture conversion.
Spanning 17 countries on five
continents, the endTB Observational
Study is the largest multicenter cohort
of patients with RR-TB or MDR-TB treated
with DLM- and BDQ-containing regimens.
We observed culture conversion by 6
months in 85% of the study population,
which was particularly remarkable given
that patients were treated under routine—
not trial—conditions and commonly had
comorbidities, XDR-TB, and/or prior
treatment for MDR-TB. These findings
underscore the importance of expanding
access to BDQ, DLM, and repurposed
drugs, such as linezolid, to patients with
RR-TB or MDR-TB throughout the world.
The lower frequency of conversion among
patients with HIV highlights the continued
need to ensure early diagnosis of, and
optimized treatment for, both conditions. n
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